These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32273545)

  • 21. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma.
    Thomas L; Smith N; Saunders D; Zalles M; Gulej R; Lerner M; Fung KM; Carcaboso AM; Towner RA
    J Transl Med; 2020 Nov; 18(1):424. PubMed ID: 33168005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
    Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
    Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma.
    Katagi H; Louis N; Unruh D; Sasaki T; He X; Zhang A; Ma Q; Piunti A; Shimazu Y; Lamano JB; Carcaboso AM; Tian X; Seluanov A; Gorbunova V; Laurie KL; Kondo A; Wadhwani NR; Lulla R; Goldman S; Venneti S; Becher OJ; Zou L; Shilatifard A; Hashizume R
    Clin Cancer Res; 2019 Sep; 25(18):5572-5583. PubMed ID: 31227500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG.
    Chiang J; Diaz AK; Makepeace L; Li X; Han Y; Li Y; Klimo P; Boop FA; Baker SJ; Gajjar A; Merchant TE; Ellison DW; Broniscer A; Patay Z; Tinkle CL
    Acta Neuropathol Commun; 2020 Apr; 8(1):57. PubMed ID: 32326973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies.
    Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A
    Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.
    Akamandisa MP; Nie K; Nahta R; Hambardzumyan D; Castellino RC
    Neuro Oncol; 2019 Jun; 21(6):786-799. PubMed ID: 30852603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
    Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
    Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma.
    Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M
    Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TSPO PET Imaging as a Potent Non-Invasive Biomarker for Diffuse Intrinsic Pontine Glioma in a Patient-Derived Orthotopic Rat Model.
    Chevaleyre C; Kereselidze D; Caillé F; Tournier N; Olaciregui NG; Winkeler A; Declèves X; Jego B; Cisternino S; Auvity S; Truillet C
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.
    Buczkowicz P; Hoeman C; Rakopoulos P; Pajovic S; Letourneau L; Dzamba M; Morrison A; Lewis P; Bouffet E; Bartels U; Zuccaro J; Agnihotri S; Ryall S; Barszczyk M; Chornenkyy Y; Bourgey M; Bourque G; Montpetit A; Cordero F; Castelo-Branco P; Mangerel J; Tabori U; Ho KC; Huang A; Taylor KR; Mackay A; Bendel AE; Nazarian J; Fangusaro JR; Karajannis MA; Zagzag D; Foreman NK; Donson A; Hegert JV; Smith A; Chan J; Lafay-Cousin L; Dunn S; Hukin J; Dunham C; Scheinemann K; Michaud J; Zelcer S; Ramsay D; Cain J; Brennan C; Souweidane MM; Jones C; Allis CD; Brudno M; Becher O; Hawkins C
    Nat Genet; 2014 May; 46(5):451-6. PubMed ID: 24705254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
    Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
    Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACVR1 mutations in DIPG: lessons learned from FOP.
    Taylor KR; Vinci M; Bullock AN; Jones C
    Cancer Res; 2014 Sep; 74(17):4565-70. PubMed ID: 25136070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG).
    Giagnacovo M; Antonelli M; Biassoni V; Schiavello E; Warmuth-Metz M; Buttarelli FR; Modena P; Massimino M
    Childs Nerv Syst; 2020 Apr; 36(4):697-704. PubMed ID: 31848724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
    Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
    PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
    Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
    Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.